Late effects of treatment for cancer during childhood and adolescence

Current Problems in Cancer

Volumn 27, Issue 3, 2003, Pages 127-142

  Green, Daniel M ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DOXORUBICIN; EPIPODOPHYLLOTOXIN; METHOTREXATE; PREDNISONE; PROCARBAZINE; THYMOCYTE ANTIBODY; VINCRISTINE;

ACUTE HEART INFARCTION; ACUTE LYMPHOBLASTIC LEUKEMIA; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOMYOPATHY; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM TUMOR; CHILDHOOD CANCER; CONGESTIVE HEART FAILURE; FERTILITY; GENETIC PREDISPOSITION; GERM CELL TUMOR; GONAD DYSFUNCTION; HEART MURMUR; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LONGEVITY; NEPHROBLASTOMA; NONHODGKIN LYMPHOMA; OSTEOSARCOMA; PERICARDITIS; PREGNANCY; REPRODUCTIVE TOXICITY; RETINOBLASTOMA; REVIEW; SARCOMA; SECOND CANCER; THYROID CARCINOMA; VALVULAR HEART DISEASE; WHOLE BODY RADIATION;

EID: 0038102382     PISSN: 01470272     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0147-0272(03)00028-X     Document Type: Review

References (99)

1. Mertens AC, Yasui Y, Neglia JP, et al. Late mortality experience in five-year survivors of childhood and adolescent cancer: The Childhood Cancer Survivor Study. J Clin Oncol 2001;19:3163-3172.
2. Hancock SL, Donaldson SS, Hoppe RT. Cardiac disease following treatment of Hodgkin's disease in children and adolescents. J Clin Oncol 1993; 11:1208-15.
3. Carlson RG, Mayfield WR, Normann S, Alexander JA. Radiation-associated valvular disease. Chest 1991;99:538-45.
4. Leonard GT, Green DM, Spangenthal EL, et al. Cardiac mortality and morbidity after treatment for Hodgkin's disease during childhood or adolescent. Pediatr Res 2000;47:46A (abstract).
5. Steinherz LJ, Steinherz PG, Tan CTC, et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991;266:1672-7.
6. Bu'Lock FA, Mott MG, Oakhill A, et al. Left ventricular diastolic function after anthracycline chemotherapy in childhood: relationship with systolic function, symptoms, and pathophysiology. Br Heart J 1995;73:340-50.
7. Green DM, Grigoriev YA, Nan B, et al. Congestive heart failure after treatment for Wilms' tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol 2001;19:1926-34.
8. Lipshultz SE, Lipsitz SR, Mone SM, et al. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995;332:1738-43.
9. Bhanot P, Cushing B, Phillipart A, et al. Hepatic irradiation and Adriamycin cardiotoxicity. J Pediatr 1979;95:561-3.
10. Pinkel D, Camitta B, Kun L, et al. Doxorubicin cardiomyopathy in children with left-sided Wilms' tumor. Med Pediatr Oncol 1982;10:483-8.
11. Sorensen K, Levitt G, Bull C, et al. Anthracycline dose in childhood acute lymphoblastic leukemia: issues of early survival versus late cardiotoxicity. J Clin Oncol 1997;15:61-8.
12. Krischer JP, Epstein S, Cuthbertson DD, et al. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J Clin Oncol 1997;15:1544-52.
13. Lipshultz SE, Colan SD, Gelber RD, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991;324:808-15.
14. Lipshultz S, Lipsitz S, Sallan S, et al. Chronic progressive left ventricular systolic dysfunction and afterload excess years after doxorubicin therapy for acute lymphoblastic leukemia. Proc Am Soc Clin Oncol 2000;19:580a (abstract).
15. Goldberg MA, Antin JH, Guinan EC, Rappeport JM. Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood 1986;68:1114-8.
16. Sanders JE, Buckner CD, Amos D, et al. Ovarian function following marrow transplantation for aplastic anemia or leukemia. Blood 1988;6:813-8.
17. Wallace WHB, Shalet SM, Crowne EC, et al. Ovarian failure following abdominal irradiation in childhood: natural history and prognosis. Clin Oncol 1989;1:75-9.
18. Scott JES. Pubertal development in children treated for nephroblastoma. J Pediatr Surg 1981;16:122-5.
19. Hamre MR, Robison LL, Nesbit ME, et al. Effects of radiation on ovarian function in long-term survivors of childhood acute lymphoblastic leukemia: a report from the Childrens Cancer Study Group. J Clin Oncol 1987;5:1759-65.
20. Wallace WHB, Shalet SM, Tetlow LJ, et al. Ovarian function following the treatment of childhood acute lymphoblastic leukemia. Med Pediatr Oncol 1993;21:333-9.
21. Andrieu JM, Ochoa-Molina ME. Menstrual cycle, pregnancies and offspring before and after MOPP therapy for Hodgkin's disease. Cancer 1983;52:435-8.
22. Chapman RM, Sutcliffe SB, Malpas JS. Cytotoxic-induced ovarian failure in Hodgkin's disease. II. Effects on sexual function. JAMA 1979;242:1882-4.
23. Waxman JHX, Terry YA, Wrigley PFM, et al. Gonadal function in Hodgkin's disease: long-term follow-up of chemotherapy. Br Med J 1982;285:1612-3.
24. Byrne J, Fears TR, Gail MH, et al. Early menopause in long-term survivors of cancer during adolescence. Am J Obstet Gynecol 1992;166:788-93.
25. Madsen BL, Giudice L, Donaldson SS. Radiation-induced premature menopause: a misconception. Int J Radiat Oncol Biol Phys 1995;32:1461-4.
26. Narayan P, Lange PH, Fraley EE. Ejaculation and fertility after extended retroperitoneal lymph node dissection for testicular cancer. J Urol 1982;127:685-8.
27. Schlegel PN, Walsh PC. Neuroanatomical approach to radical cystoprostatectomy with preservation of sexual function. J Urol 1987;138:1402-6.
28. Shalet SM, Beardwell CG, Jacobs HS, et al. Testicular function following irradiation of the human prepubertal testis. Clin Endocrinol 1978;9:483-90.
29. Blatt J, Sherins RJ, Niebrugge D, et al. Leydig cell function in boys following treatment for testicular relapse of acute lymphoblastic leukemia. J Clin Oncol 1985;3:1227-31.
30. Chapman RM, Sutcliffe SB, Malpas JS. Male gonadal dysfunction in Hodgkin's disease. JAMA 1981;245:1323-8.
31. Chapman RM, Rees LH, Sutcliffe SB, et al. Cyclical combination chemotherapy and gonadal function. Lancet 1979;1:285-9.
32. da Cunha MF, Meistrich ML, Fuller LM, et al. Recovery of spermatogenesis after treatment for Hodgkin's disease: limiting dose of MOPP chemotherapy. J Clin Oncol 1984;2:571-7.
33. Braumswig JH, Heimes U, Heiermann E, et al. The effects of different cumulative doses of chemotherapy on testicular function. Results in 75 patients treated for Hodgkin's disease during childhood or adolescence. Cancer 1990;65:1298-302.
34. Byrne J, Mulvihill JJ, Myers MH, et al. Effects of treatment on fertility in long-term survivors of childhood or adolescent cancer. N Engl J Med 1987;317:1315-21.
35. Critchley HOD, Wallace WHB, Shalet SM, et al. Abdominal irradiation in childhood: the potential for pregnancy. Br J Obstet Gynecol 1992;99:392-4.
36. Critchley HOD. Factors of importance for implantation and problems after treatment for childhood cancer. Med Pediatr Oncol 1999;33:9-14.
37. Bath LE, Critchley HO, Chambers SE, et al. Ovarian and uterine characteristics after total body irradiation in childhood and adolescence: response to sex steroid replacement. Br J Obstet Gynaecol 1999;106:1265-72.
38. Li FP, Fine W, Jaffe N, et al. Offspring of patients treated for cancer in childhood. J Natl Cancer Inst 1979;62:1193-7.
39. Hawkins MM, Smith RA, Curtice LJ. Childhood cancer survivors and their offspring studied through a postal survey of general practitioners: preliminary results. J R Coll Gen Pract 1988;38:102-5.
40. Byrne J, Rasmussen SA, Steinhorn SC, et al. Genetic disease in offspring of long-term survivors of childhood and adolescent cancer. Am J Hum Genet 1998;62:45-52.
41. Green DM, Fine WE, Li FP. Offspring of patients treated for unilateral Wilms' tumor in childhood. Cancer 1982;49:2285-8.
42. Byrne J, Mulvihill JJ, Connelly RR, et al. Reproductive problems and birth defects in survivors of Wilms' tumor and their relatives. Med Pediatr Oncol 1988;16:233-40.
43. Li FP, Gimbrere K, Gelber RD, et al. Outcome of pregnancy in survivors of Wilms' tumor. JAMA 1987;257:216-9.
44. Hawkins MM, Smith RA. Pregnancy outcomes in childhood cancer survivors: probable effects of abdominal irradiation. Int J Cancer 1989;43:399-402.
45. Hawkins MM. Is there evidence of a therapy-related increase in germ cell mutation among childhood cancer survivors'? J Natl Cancer Inst 1991;83:1643-50.
46. Green DM, Zevon MA, Lowrie G, et al. Pregnancy outcome following treatment with chemotherapy for cancer in childhood and adolescence. N Engl J Med 1991;325:141-6.
47. Nygaard R, Clausen N, Siimes MA, et al. Reproduction following treatment for childhood leukemia: a population-based prospective cohort study of fertility and offspring. Med Pediatr Oncol 1991;19:459-66.
48. Dodds I, Marrett LD, Tomkins DJ, et al. Case-control study of congenital anomalies in children of cancer patients. Br Med J 1993;307:164-8.
49. Kenny LB, Nicholson HS, Brasseux C, et al. Birth defects in offspring of adult survivors of childhood acute lymphoblastic leukemia. Cancer 1996;78:169-76.
50. Green DM, Fiorello A, Zevon MA, et al. Birth defects and childhood cancer in offspring of survivors of childhood cancer. Arch Pediatr Adolesc Med 1997;151:379-83.
51. Mulvihill JJ, Myers MH, Connelly RR, et al. Cancer in offspring of long-term survivors of childhood and adolescent cancer. Lancet 1987;2:813-7.
52. Hawkins JJ, Draper GJ, Smith RA. Cancer among 1,348 offspring of survivors of childhood cancer. Int J Cancer 1989;43:975-8.
53. Sanders JE, Hawley J, Levy W, et al. Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation. Blood 1996;87:3045-52.
54. Green DM, Whitton JA, Stovall M, et al. Pregnancy outcome of partners of male survivors of childhood cancer. A report from the Childhood Cancer Survivor Study. J Clin Oncol 2003;21:716-21.
55. Green DM, Whitton JA, Stovall M, et al. Pregnancy outcome of female survivors of childhood cancer. A report from the Childhood Cancer Survivor Study. Am J Obstet Gynecol 2002;187:1070-80.
56. Tucker MA, Meadows AT, Boice JD, et al. Cancer risk following treatment of childhood cancer. Boice JD Jr, Fraumeni JF Jr, editors. Radiation carcinogenesis, epidemiology and biological significance. New York: Raven Press, 1984:211.
57. Hawkins MM, Draper GJ, Kingston JE. Incidence of second primary tumors among childhood cancer survivors. Br J Cancer 1987;56:339-47.
58. de Vathaire F, Schweisguth O, Rodary C, et al. Long-term risk of a second malignant neoplasm after a cancer in childhood. Br J Cancer 1989;59:448-52.
59. Green DM, Zevon MA, Reese PA, et al. Second malignant tumors following treatment during childhood and adolescence for cancer. Med Pediatr Oncol 1994;22:1-10.
60. Olsen JH, Garwicz S, Hertz H, et al. Second malignant neoplasms after cancer in childhood or adolescence. Br Med J 1993;307:1030-6.
61. Wong FL, Boice JD Jr, Abramson DH, et al. Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA 1997;278:1262-7.
62. Li FP, Fraumeni JF Jr, Mulvihill JJ, et al. A cancer family syndrome in twenty-four kindreds. Cancer Res 1988;48:5358-62.
63. Law JC, Strong LC, Chidambaram A, Ferrell RE. A germ line mutation in exon 5 of the p53 gene in an extended cancer family. Cancer Res 1992;51:6385-7.
64. Santibanez MF, Birch JM, Hartley AL, et al. p53 germline mutations in LiFraumeni syndrome. Lancet 1991;338:1490-1.
65. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas and other neoplasms. Science 1990;250:1233-8.
66. Srivastava S, Zou Z, Pirollo K, et al. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 1990;348:747-9.
67. Bell DW, Varley JM, Szydlo TE, et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 1999;286:2528-31.
68. Lee SB, Kim SH, Bell DW, et al. Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni syndrome. Cancer Res 2001;61:8062-7.
69. Malkin D, Jolly KW, Barbier N, et al. Germ line mutations of the p53 tumorsuppressor gene in children and young adults with second malignant neoplasms. N Engl J Med 1992;326:1309-15 (correction 1997;336:734).
70. Breslow NE, Takashima JR, Whitton JA, et al. Second malignant neoplasms following treatment for Wilms tumor: a report from the National Wilms Tumor Study Group. J Clin Oncol 1995;13:1851-9.
71. Wikstrom S, Parkkulainen KV, Louhimo I. Bilateral Wilms' tumor and secondary malignancy. J Pediatr Surg 1982;17:269-72.
72. Green DM, Hyland A, Barcos MP, et al. Second malignant neoplasms after treatment for Hodgkin disease in childhood or adolescence. J Clin Oncol 2000;18:1492-9.
73. Sankila R, Garwicz S, Olsen JH, et al. Risk of subsequent malignant neoplasms among 1,641 Hodgkin's disease patients diagnosed in childhood and adolescence: a population-based cohort study in the five Nordic countries. J Clin Oncol 1996;14:1442-6.
74. Wolden SL, Lamborn KR, Cleary SF, et al. Second cancers following pediatric Hodgkin's disease. J Clin Oncol 1998;16:536-44.
75. Bhatia S, Robision LL, Oberlin O, et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med 1996;334:745-51.
76. Rimm IJ, Li FP, Tarbell NJ, et al. Brain tumors after cranial irradiation for childhood acute lymphoblastic leukemia. Cancer 1987;59:1506-8.
77. Nygaard R, Garwicz S, Haldorsen T, et al. Second malignant neoplasms in patients treated for childhood leukemia. Acta Paediatr Scand 1991;80:1220-8.
78. Neglia JP, Meadows AT, Robison LL, et al. Second neoplasms after acute lymphoblastic leukemia in childhood. N Engl J Med 1991;325:1330-6.
79. Tucker MA, D'Angio GJ, Boice JD Jr, et al. Bone sarcomas linked to radiotherapy and chemotherapy in children. N Engl J Med 1987;317:588-93.
80. Kuttesch JF Jr, Wexler LH, Marcus RB, et al. Second malignancies after Ewing's sarcoma: radiation dose-dependency of secondary sarcomas. J Clin Oncol 1996; 14:2818-25.
81. Hudson MM, Poquette CA, Lee J, et al. Increased mortality after successful treatment for Hodgkin's disease. J Clin Oncol 1998;16:3592-600.
82. Bhatia S, Robison LL, Oberlin O, et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med 1996;334:745-51.
83. Travis LB, Curtis RE, Boice JD Jr. Late effects of treatment for childhood Hodgkin's disease. N Engl J Med 1996;335:352-3 (letter).
84. Bhatia S, Ramsay NKC, Steinbuch M, et al. Malignant neoplasms following bone marrow transplantation. Blood 1996;87:3633-9.
85. Donaldson SS, Link MP. Combined modality treatment with low-dose radiation and MOPP chemotherapy for children with Hodgkin's disease. J Clin Oncol 1987;5:742-9.
86. Schellong G, Riepenhausen M, Creutzig U, et al. Low risk of secondary leukemias after chemotherapy without mechlorethamine in childhood Hodgkin's disease. J Clin Oncol 1997;15:2247-53.
87. Tucker MA, Meadows AT, Boice JD Jr, et al. Leukemia after therapy with alkylating agents for childhood cancer. J Natl Cancer Inst 1987;78:459-64.
88. Pui C-H, Ribaeiro RC, Hancock ML, et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med 1991;325:1682-7.
89. Pedersen-Bjergaaard J, Daugaaard G, Hansen SW, et al. Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ cell tumours. Lancet 1991;338:359.
90. Winick NJ, McKenna RW, Shuster JJ, et al. Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide. J Clin Oncol 1993;11:209-17.
91. Sugita K, Furukawa T, Tsuchida M, et al. High frequency of etoposide (VP-16)-related secondary leukemia in children with non-Hodgkin's lymphoma. Am J Pediatr Hematol Oncol 1993;15:99-104.
92. Hawkins MM, Kinnier Wilson LM, Stovall MA, et al. Epipodophyllotoxins, alkylating agents and radiation and risk of secondary leukaemia after childhood cancer. Br Med J 1992;304:951-8.
93. Neglia JP, Friedman DL, Yasui Y, et al. Second malignant neoplasms in five-year survivors of childhood cancer: Childhood Cancer Survivor Study. J Natl Cancer Inst 2001;93:618-29.
94. Grundy R, Gosden RG, Hewitt M, et al. Fertility preservation for children treated for cancer (1): scientific advances and research dilemnas (2): ethics of consent for gamete storage and experimentation. Arch Dis Child 2001;84:355-9.
95. Wallace WHB, Walker DA. Conference consensus statement: ethical and research dilemmas for fertility preservation in children treated for cancer. Human Fertil 2001;4:69-76.
96. Mulhern RK, Tyc VL, Phipps S, et al. Health-related behaviors of survivors of childhood cancer. Med Pediatr Oncol 1995;25:159-65.
97. Haupt R, Byrne J, Connelly RR, et al. Smoking habits in survivors of childhood and adolescent cancer. Med Pediatr Oncol 1992;20:301-6.
98. Tao ML, Guo MD, Weiss R, et al. Smoking in adult survivors of childhood acute lymphoblastic leukemia. J Natl Cancer Inst 1998;90:219-25.
99. Emmons K, Li FP, Whitton J, et al. Predictors of smoking initiation and cessation among childhood cancer survivors: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2002;20:1608-16.